P02.01.B The telomere maintenance mechanism spectrum and its dynamics in gliomas. (5th September 2022)

• Record Type: Journal Article
• Authors: Kim, S; Chowdhury, T; Yu, H; Choi, S; Kim, K; Kang, H; Lee, J; Lee, S; Won, J; Kim, K; Kim, K; Kim, M; Lee, J; Kim, J; Kim, Y; Kim, T; Choi, S; Phi, J; Shin, Y; Ku, J; Lee, S; Yun, H; Lee, H; Kim, D; Kim, K; Hur, J K; Park, S; Kim, S; Park, C
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 2
• Page Start: ii29
• Page End: ii29
• Publication Date: 2022-09-05
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac174.094
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: The activation of the telomere maintenance mechanism (TMM) is one of the critical drivers of cancer cell immortality. In gliomas, TERT expression and TERT promoter mutation are considered to reliably indicate telomerase activation, while ATRX mutation indicates alternative lengthening of telomeres (ALT). However, these relationships have not been extensively validated in tumor tissues. Here, we show through the direct measurement of telomerase activity and ALT in a large set of glioma samples that the TMM in glioma cannot be defined in the dichotomy of telomerase activity and ALT, regardless of TERT expression, TERT promoter mutation and ATRX mutation. Moreover, we observed that a considerable proportion of gliomas lack both telomerase activity and ALT (Neither group). And this Neither group exhibited evidence of slow growth potential. From a set of longitudinal samples from a separate cohort of glioma patients, we discovered that the TMM is not fixed but changes with glioma progression. Collectively, these results suggest that the TMM is a dynamic entity and that reflects the plasticity of the oncogenic biological status of tumor cells and that the TMM should be defined by the direct measurement of telomerase enzyme activity and evidence of ALT.